Sec Form 4 Filing - Blanchard Cheryl R @ Anika Therapeutics, Inc. - 2023-03-09

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Blanchard Cheryl R 2. Issuer Name and Ticker or Trading Symbol Anika Therapeutics, Inc. [ ANIK] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) President, CEO, Director (Last) (First) (Middle) 32 WIGGINS AVENUE 3. Date of Earliest Transaction (MM/DD/YY) 03/09/2023 (Street) BEDFORD, MA01730 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 03/09/2023 M 14,419 ( 1 ) A $ 0 87,963 ( 2 ) D Common Stock 03/09/2023 F 4,232 ( 3 ) D $ 26.91 ( 4 ) 83,731 D Common Stock 11,742 ( 5 ) I Revocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Restricted Stock Unit $ 0 03/09/2023 A 60,004 ( 6 ) ( 6 ) Common Stock 60,004 $ 0 60,004 D Stock Option (Right to Buy) $ 29.6 ( 7 ) 03/09/2023 A 130,998 ( 8 ) 03/09/2033 Common Stock 130,998 $ 0 130,998 D Restricted Stock Unit $ 0 03/09/2023 M 14,419 ( 9 ) ( 9 ) Common Stock 14,419 $ 0 14,420 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Blanchard Cheryl R 32 WIGGINS AVENUE BEDFORD, MA01730 X President, CEO, Director Signatures /s/ Cheryl R. Blanchard 03/10/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Reflects the second vesting installment of Restricted Stock Units (RSUs) granted on March 9, 2021. ( 2 )Includes the following shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan: 540 shares purchased on May 13, 2022 and 178 shares purchased on November 14, 2022. ( 3 )Reflects an aggregate of 4,232 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2023. ( 4 )Reflects the closing price of ANIK common stock on March 9, 2023, the trading day on which the vesting of RSUs gave rise to tax withholding obligations. ( 5 )Consists of shares transferred by Dr. Blanchard to The Cheryl R. Blanchard Amended and Restated Revocable Trust dated December 19, 2014, of which Dr. Blanchard is a beneficiary and the sole trustee. ( 6 )Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024. ( 7 )Represents a 10% premium above the closing price of Anika's common stock on the date of grant. ( 8 )The premium priced stock options vest in three equal annual installments beginning on March 9, 2024. ( 9 )Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.